Paul Tudor Jones's ALLO Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 71,008 shares of Allogene Therapeutics, Inc. (ALLO) worth $97,281, representing 0.00% of the portfolio. First purchased in 2020-Q2, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in ALLO, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2022, adding 99,356 shares. Largest reduction occurred in Q2 2022, reducing 171,247 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Allogene Therapeutics (ALLO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Allogene Therapeutics (ALLO) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2025 | +71,008 | New Buy | 71,008 | $1.46 |
| Q3 2024 | -71,340 | Sold Out | 0 | $0.00 |
| Q2 2024 | -412 | Reduce 0.57% | 71,340 | $2.33 |
| Q1 2024 | +71,752 | New Buy | 71,752 | $4.47 |
| Q4 2023 | -73,998 | Sold Out | 0 | $0.00 |
| Q3 2023 | +63,135 | Add 581.19% | 73,998 | $3.17 |
| Q2 2023 | +10,863 | New Buy | 10,863 | $4.97 |
| Q1 2023 | -77,228 | Sold Out | 0 | $0.00 |
| Q4 2022 | +60,175 | Add 352.87% | 77,228 | $0.01 |
| Q3 2022 | +17,053 | New Buy | 17,053 | $10.79 |
| Q2 2022 | -171,247 | Sold Out | 0 | $0.00 |
| Q1 2022 | +99,356 | Add 138.20% | 171,247 | $9.11 |
| Q4 2021 | +71,891 | New Buy | 71,891 | $14.93 |
| Q3 2021 | -98,912 | Sold Out | 0 | $0.00 |
| Q2 2021 | +98,912 | New Buy | 98,912 | $26.08 |
| Q1 2021 | -12,120 | Sold Out | 0 | $0.00 |
| Q4 2020 | +1,197 | Add 10.96% | 12,120 | $25.25 |
| Q3 2020 | -39,476 | Reduce 78.33% | 10,923 | $37.72 |
| Q2 2020 | +50,399 | New Buy | 50,399 | $42.82 |
Paul Tudor Jones's Allogene Therapeutics Investment FAQs
Paul Tudor Jones first purchased Allogene Therapeutics, Inc. (ALLO) in Q2 2020, acquiring 50,399 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Allogene Therapeutics, Inc. (ALLO) for 22 quarters since Q2 2020.
Paul Tudor Jones's largest addition to Allogene Therapeutics, Inc. (ALLO) was in Q1 2022, adding 171,247 shares worth $1.56 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 71,008 shares of Allogene Therapeutics, Inc. (ALLO), valued at approximately $97,281.
As of the Q4 2025 filing, Allogene Therapeutics, Inc. (ALLO) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Allogene Therapeutics, Inc. (ALLO) was 171,247 shares, as reported at the end of Q1 2022.